Stephen Anindo connects B2B companies the moment a public trigger fires, an FDA letter, a hiring surge, a production line on the move, with the operators built for exactly that moment.
Public trigger data across three B2B lanes: FDA enforcement, hiring data, production shifts. Updated as it publishes.
- →FDA warning letters hit two sterile makers, Bausch & Lomb and NexCell Scientific, over aseptic processing: September 2026
- →Contract manufacturer kdc/one Chatsworth cited by FDA for releasing OTC product without required testing: September 2026
- →Boston Scientific files a restructuring that moves production lines between plants, $700M to $800M in charges: July 2026
- →US manufacturing job openings jump from 501,000 to 580,000 in a single month: July 2026
Sourced from FDA warning letters, SEC EDGAR filings, and BLS JOLTS data, July to September 2026.
No deal to point at yet — so here’s exactly what I put in motion.
- Triggered company → the operator who fixes it When a warning letter lands, a line moves, or a hiring plan stalls, the clock starts. I put a vetted specialist in the room that week, while the problem is still small.
- Operator → the companies who need them now If you remediate quality systems, validate production lines, or place hard-to-find talent, I bring you the companies who just learned they need you, the day they learn it.
Building in the open. I’m working alongside myoProcess — a vetted B2B partner trusted across $1B+ in transactions — while I route my first introductions in this lane. My first closed match replaces this paragraph.
What I see in this market that outsiders miss.